Robert S. Mcdowell

Robert McDowell has over three decades of experience discovering small molecule drugs in cardiovascular disease, inflammation and oncology, with seven compounds advancing into clinical trials. Dr. McDowell has been an integral part of MyoKardia since its inception in 2012, having served as Senior Vice President of Drug Discovery through October 2017, when he was promoted to his current position. Prior to joining MyoKardia, Dr. McDowell led drug discovery at 3-V Biosciences, advancing the company's lead program into development. He previously served as vice president of research at Sunesis Pharmaceuticals, where he oversaw drug discovery, translational research and manufacturing functions. Dr. McDowell led the structural chemistry group at Axys Pharmaceuticals. Before joining Axys, Dr. McDowell was a senior scientist at Genentech, where he developed successful strategies for peptidomimetic design. Dr. McDowell has authored more than 40 peer-reviewed manuscripts and is an inventor on more than 20 issued U.S. patents.

Dr. McDowell holds a B.S. in chemistry and physics from Butler University and a Ph.D. in chemistry from the University of California at Berkeley.